We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca Releases “Pooled Analysis” Phase 3 Data on COVID-19 Vaccine
AstraZeneca Releases “Pooled Analysis” Phase 3 Data on COVID-19 Vaccine
AstraZeneca (AZ) and the University of Oxford have presented new data from a “pooled analysis” of phase 3 trials evaluating COVID-19 vaccine AZD1222 at two different dose regimens, demonstrating an average efficacy of 70.4 percent.